Moringa Acquisition Stock Price, News & Analysis
MACAU
NASDAQ
Company Description
Moringa Acquisition Corp (MACAU) is a blank check company focused on effecting a merger or business combination with Israel-related technology companies. Recently, Moringa announced a proposed merger with Silexion Ltd, an oncology-focused biotechnology company. Silexion's product, Loder™, has shown promising results in a Phase 2a clinical trial for non-resectable pancreatic cancer. The business combination is expected to close in the third quarter of 2024, subject to customary closing conditions and regulatory approvals.
Stock Performance
$—
0.00%
0.00
Last updated:
4.91 %
Performance 1 year
$0.0
Market Cap
12.0M
Shares outstanding
Latest News
SEC Filings
No SEC filings available for Moringa Acquisition.
Financial Highlights
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin
Upcoming Events
Frequently Asked Questions
What is the current stock price of Moringa Acquisition (MACAU)?
The current stock price of Moringa Acquisition (MACAU) is $13.05 as of February 7, 2025.
What is Moringa Acquisition Corp (MACAU)?
Moringa Acquisition Corp is a blank check company focused on merging with Israel-related technology companies.
What recent announcement did Moringa make?
Moringa announced a proposed merger with Silexion Ltd, an oncology-focused biotechnology company.
What is Silexion's product Loder™?
Loder™ is Silexion's first-generation product showing promising results in a Phase 2a clinical trial for non-resectable pancreatic cancer.
When is the business combination expected to close?
The business combination is expected to close in the third quarter of 2024, subject to regulatory approvals.
Who is the CEO of Moringa Acquisition Corp?
Ilan Levin is the Chief Executive Officer and Chairman of Moringa Acquisition Corp.
How many shares will Moringa issue to Silexion's current equity holders?
Moringa will issue 6.25 million shares (on a fully-diluted basis) to Silexion's current equity holders.
How many members will be on the combined company's board of directors?
The combined company's board of directors will consist of seven members, two appointed by Moringa's sponsor.
What is the focus of Silexion Therapeutics?
Silexion Therapeutics is focused on developing innovative treatments for solid tumor cancers with the mutated KRAS oncogene.
Who are the legal counsels for Moringa Acquisition Corp and Silexion?
Meitar | Law Offices and Greenberg Traurig are legal counsels for Moringa, and Herzog Fox & Neeman is the legal counsel for Silexion.
Where can shareholders find more information about the proposed business combination?
Shareholders can find more information on the SEC's website or the Investor Relations section of the Moringa website.